BLPH:NAS (USA) Also trade in: Germany

Bellerophon Therapeutics Inc

$ 0.65 0 (-0.26%)
Volume: 68,507 Avg Vol (1m): 258,666
Market Cap $: 44.89 Mil Enterprise Value $: 28.25 Mil
P/E (TTM): 0.00 P/B: 10.48
Earnings Power Value 0.26
Net Current Asset Value 0.05
Tangible Book 0.06
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt No Debt
N/A
Interest Coverage No Debt
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -11.43
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 9.95%

Profitability & Growth : 4/10

Current vs industry vs history
ROA % 9.74
ROC (Joel Greenblatt) % -3299.41
3-Year Total EBITDA Growth Rate 16.80
3-Year EPS w/o NRI Growth Rate 55.20

» BLPH's 30-Y Financials

Financials (Next Earnings Date: 2019-05-10)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BLPH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:CERC NAS:SRRA XTAE:RDHL ROCO:4130 NAS:INFI LSE:MTFB NAS:KMPH LSE:ERGO NAS:CRIS XTAE:CBI TPE:4737 OTCPK:DGJI XPAR:ADOC WAR:BIO ROCO:6589 NAS:ALPN XSWX:SANN TSE:2191 NAS:AVXL NAS:ZYNE
Traded in other countries 6L7.Germany
Address 184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059
Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. The company develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. Its products are aimed at the treatment of different kinds of pulmonary hypertension.

Ratios

Current vs industry vs history
Price-to-Owner-Earnings 6.44
PB Ratio 10.48
EV-to-EBIT -1.01
EV-to-EBITDA -1.03
Current Ratio 2.31
Quick Ratio 2.31

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -70.50

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 10.83
Earnings Yield (Joel Greenblatt) % -99.01

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA Y
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N